| Literature DB >> 32616192 |
Yu-Chi Chen1, Mu-Yang Huang1, Le-Le Zhang2, Zhe-Ling Feng1, Xiao-Ming Jiang1, Luo-Wei Yuan1, Run-Yue Huang3, Bo Liu3, Hua Yu1, Yi-Tao Wang1, Xiu-Ping Chen1, Li-Gen Lin1, Jin-Jian Lu4.
Abstract
Nagilactone E (NLE), a natural product with anticancer activities, is isolated from Podocarpus nagi. In this study, we reported that NLE increased programmed death ligand 1 (PD-L1) expressions at both protein and mRNA levels in human lung cancer cells, and enhanced its localization on the cell membrane. Mechanistically, NLE increased the phosphorylation and expression of c-Jun, and promoted the localization of c-Jun in the nucleus, while silencing of c-Jun by small interfering RNA (siRNA) reduced NLE-induced PD-L1. Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1. Moreover, NLE-induced PD-L1 increased the binding intensity of PD-1 on the cell surface. In summary, NLE upregulates the expression of PD-L1 in lung cancer cells through the activation of JNK-c-Jun axis, which has the potential to combine with the PD-1/PD-L1 antibody therapies in lung cancer.Entities:
Keywords: JNK; Lung cancer; Nagilactone E; Programmed death ligand 1; c-Jun
Year: 2020 PMID: 32616192 DOI: 10.1016/S1875-5364(20)30062-5
Source DB: PubMed Journal: Chin J Nat Med ISSN: 1875-5364